{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263617","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.256716+00:00","generated_at":"2026-05-17T00:46:55.913740+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Heron Q3 net revenue $38.2M, acute care +67% YoY, FY guidance reaffirmed","bullets":["Q3 net revenue $38.2M (+16.5% YoY); YTD $114.3M.","ZYNRELEF net revenue $9.3M (+49% YoY); APONVIE $3.0M (+173% YoY).","FY 2025 guidance reaffirmed: net revenue $153-163M, adj. EBITDA $9-13M.","J-code for ZYNRELEF effective Oct 1, 2025; VAN transition complete.","Cash and investments $55.5M as of Sept 30, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263617","json":"https://secwatch.observer/filing/0001193125-25-263617.json","markdown":"https://secwatch.observer/filing/0001193125-25-263617.md","text":"https://secwatch.observer/filing/0001193125-25-263617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/0001193125-25-263617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000119312525263617/hrtx-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:46:55.913740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}